Guardant Health will present data at ESMO 2021 demonstrating the utility of Guardant360 liquid biopsy for obtaining comprehensive molecular information to guide target treatment options for stage …

Class in: Science and technology, Sant
Topics : Conference, Product/Service, Trade Show

Guardant Health to Present Data Demonstrating Usefulness of Guardant360 Liquid Biopsy at ESMO 2021 for comprehensive molecular information to guide target therapy options for advanced stage cancers

Guardant Health, Inc. (Nasdaq: GH), and leading academic and pharmaceutical institutions to share data highlighting important molecular targets, patterns of treatment resistance, and benefits of using the drug. liquid biopsy Guardant360 to help improve the management of advanced solid cancers, during the 2021 virtual congress of the European Society for Medical Oncology (ESMO) to be held from September 16 to 21.

While precision oncology has greatly contributed to improved clinical outcomes for very common cancers, such as non-small cell lung cancer, colorectal cancer, and breast cancer, there remains a subset of patients who do not respond to currently available treatments, said Craig Eagle, MD, chief medical officer of Guardant Health. It is gratifying to be able to work with the oncology community to analyze the molecular information generated by our liquid biopsy tests in order to continue to improve our understanding of possible new targets and more personalized treatments potentially capable of more constructively improving the overall survival of the patient. these difficult cancer patients to treat.

Guardant INFORMtm Liquid Biopsy Data Set Shows No Clear Standard Of Care And Unmet Need For Patients With HER2 + Metastatic Colorectal Cancer

Title

e-Poster

Presenter

Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study [Caractristiques et schmas thrapeutiques chez les patients atteints d’un cancer colorectal avanc/mtastatique (CCRm) avec amplification du gne HER2 : Une tude de base de donnes clinico-gnomique]

439P

John Strickler

Guardant360 Liquid Biopsy Reveals Molecular Insights Impacting Outcomes in Patients with Unresectable and Early-Onset (<50 years) Metastatic Colorectal Cancer [La biopsie liquide Guardant360 rvle des informations molculaires ayant un impact sur les rsultats des patients atteints d’un cancer colorectal mtastatique non rscable et dclenchement prcoce (< 50 ans)]

Title

e-Poster

Presenter

Molecular features in liquid biopsy of early (EO) and late-onset colorectal cancer (LO) (Caractristiques molculaires de la biopsie liquide des cancers colorectaux dclenchement prcoce et dclenchement tardif)

500P

Julia Alcaide-Garcia

Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR) [Paysage mutationnel dans le cancer colorectal mtastatique (CRCm) synchrone non rscable en fonction de la rsection initiale de la tumeur primitive]

503P

Manuel Benavides

Guardant360 Liquid Biopsy Reveals Treatment Resistance Patterns and Therapeutic Targets for the Management of Advanced Cancers Including Non-Small Cell Lung and Pancreatic non-small cell lung cancer and pancreatic cancer)

Title

e-Poster

Presenter

First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA) [Premiers rsultats de l’tude CLIMB360, un programme de dpistage molculaire prospectif de plusieurs types de cancer sur la base de l’ADN tumoral circulant (ADNtc)]

92P

Javier Garcia-Corbacho

Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)

1196P

Ben J. Solomon

Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer

1483P

Pedro Uson Junior

about Guardant Health

Guardant Health is a leading precision oncology company dedicated to helping defeat cancer on a global scale through the use of its proprietary blood tests, extensive data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient outcomes, and reduce health costs at all stages of the cancer care continuum. Guardant Health commercially launched Guardant360 tests, Guardant360 CDx, Guardant360 TissueNexttm, Guardant360 Responsetm, in addition to the GuardantOMNI tests for patients with advanced cancer, and the Guardant Revealtm test for patients with early stage. These tests promote the development of its LUNAR screening program, the objective of which is to meet the needs of asymptomatic people eligible for cancer screening.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Federal securities laws, including statements regarding the possible uses, and the potential values, benefits and advantages of Guardant Health’s liquid biopsy tests or trials, which involve risks and uncertainties that could lead to a material difference between actual results and the expected results or the expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual results could differ materially from these statements due to a number of factors. These and other risks and uncertainties that may affect Guardant Health’s financial and operating results, and lead to actual results materially different from those indicated by the forward-looking statements in this press release, include those described under the headings Risk Factors and Management Discussion and Analysis of Financial Position and Results of Operations as well as in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and in its other reports filed to the Securities and Exchange Commission, including its Quarterly Reports on Form 10-K for the fiscal year ended March 31, 2021 and for the fiscal year ended June 30, 2021. The forward-looking statements contained in this press release are based on information made available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements fo urns to reflect any change in its expectations, or any change in events, conditions or circumstances upon which such statement is based, except as required by law. These forward-looking statements do not form a sufficiently reliable basis to represent the views of Guardant Health as of any date subsequent to the date of this press release.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the communiqu is that of the communiqu in its original language. The translation will always have to be compared to the source text, which will set a precedent.

These press releases may also be of interest to you

21:25

Since 2020, the global pandemic has not made going out to restaurants easier. Getting delivered or ordering takeout can quickly increase the bill, but also the calories unnecessarily provided by fats, sugar and salt. so much …

21:20

Guardant Health will present data at ESMO 2021 demonstrating the utility of Guardant360 liquid biopsy for obtaining comprehensive molecular information to guide target treatment options for stage …

21:09

The global pandemic since 2020 has not made dining out easier. The costs associated with constant orders for delivery or take out can add up quickly, as can the calories consumed from fat, …

20:42

Alithya Group Inc. (Alithya) held virtually today its annual and special general meeting of shareholders (the meeting). In total, 48,282,749 Class A subordinate voting shares and 7,321,616 shares …

19:55

The Burgiss Group, LLC (Burgiss) and Caissa, LLC (Caissa) announced today that they have reached a definitive agreement to merge their businesses. On a cumulative basis, the company will become one of the world leaders in …

19:05

PsiOxus Therapeutics, Ltd. (PsiOxus), a tumor reprogramming company, today announced that it will present key safety and translational data from its first FORTITUDE phase 1 human clinical study at the congress …

Press release sent on September 15, 2021 9:20 pm and distributed by:

 
For Latest Updates Follow us on Google News
 

NEXT of Lyonnais regenerate lost neurons